International Journal of Clinical Case Reports 2024, Vol.14, No.2, 79-86 http://medscipublisher.com/index.php/ijccr 86 resistance, working towards the development of more targeted treatment strategies to extend the effectiveness of treatments for patients. Collaboration and interdisciplinary research will also play a crucial role in fostering innovation and advancement in targeted therapy. References Bai L.J., Gao B.S., Jia W.L., Hou L.H., Zhang Z.W., Deng H.G., Zhao L.X., and Liu D., 2022, PROTACs: advanced strategy of targeted therapy in cancer, Zhongguo Yaowu Huaxue Zazhi (Chinese Journal of Medicinal Chemistry), 32(7): 529-537. Block J.R.M., and McGronohon N., 2021, Genetic and non-genetic clonal diversity in cancer evolution, Nat. Rev. Cancer, 21(6): 379-392. https://doi.org/10.1038/s41568-021-00336-2 Claudiani S., Apperley J.F., Szydlo R., Khan A., Nesr G., Hayden C., Innes A.J., Dominy K., Foskett P., Foroni L., Khorashad J., and Milojkovic D., 2021, TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia, Brit. J. Haematol., 193(2): 346-355. https://doi.org/10.1111/bjh.17286 Goto K., Yoshikawa S., Kiyohara Y., Kukita Y., Miura K., and Oishi T., 2022, Co-existence of BRAF V600E-mutated malignant melanoma and BRAF V600E-mutated Langerhans cell histiocytosis: A case report, J. Cutan. Pathol., 49(4): 393-398. https://doi.org/10.1111/cup.14171 Jacob S.A., Do V., and Wilson B.E., 2021, The value of first-line chemotherapy and targeted therapy in the treatment of breast cancer, Eur. J. Cancer Care, 30(1): e13352. https://doi.org/10.1111/ecc.13352 Kiyotani K., Toyoshima Y., and Nakamura Y., 2021, Personalized immunotherapy in cancer precision medicine, 18(4): 955-965. https://doi.org/10.20892/j.issn.2095-3941.2021.0032 Li Z., Sun Y., and Qian Q.J., 2019, Immunotherapy precise targeting tumour microenvironment will become a key strategy of curing cancer, Zhongguo Zhongliu Shengwu Zhiliao Zazhi (Chinses Journal of Cancer Biotherapy), 26(1): 7-15. Pan X.Y., and Xiong X.Y., 2022, Advances in nuclear targeting nano-drug carriers for cancer therapy, Jiangxi Keji Shifan Daxue Xuebao (Journal of Jiangxi Science&Technology Normal University), 6: 64-70. Song Y.F., Luo L., Shi P.C., Li Z.Z., Zhang T.G., Cao Y.P., and Zhu X.J., 2023, Effect of Cyr61 on Imatinib Resistance in Chronic Myeloid Leukemia and Its Mechanism, Zhongguo Shiyan Xueyexue Zazhi (Journal of Experimental Hematology), 31(1): 1-7. Zhang Y.P., and Liu B.G., 2022, Resistance characteristics and countermeasures of targeted therapy in non -small cell lung cancer, Xiandai Zhongliu Yixue (Journal of Modern Oncology), 30(20): 3830-3834.
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==